These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Thromboprophylaxis for children hospitalized with COVID-19 and MIS-C. Schmitz AH; Wood KE; Burghardt EL; Koestner BP; Wendt LH; Badheka AV; Sharathkumar AA Res Pract Thromb Haemost; 2022 Jul; 6(5):e12780. PubMed ID: 35949885 [TBL] [Abstract][Full Text] [Related]
4. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
5. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333 [TBL] [Abstract][Full Text] [Related]
6. Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Sochet AA; Morrison JM; Jaffray J; Godiwala N; Wilson HP; Thornburg CD; Bhat RV; Zia A; Lawrence C; Kudchadkar SR; Hamblin F; Russell CJ; Streiff MB; Spyropoulos AC; Amankwah EK; Goldenberg NA; Pediatrics; 2022 Jul; 150(1):. PubMed ID: 35484817 [TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. Dobbie LJ; Lamb A; Eskell L; Ramage IJ; Reynolds BC Pediatr Nephrol; 2021 May; 36(5):1183-1194. PubMed ID: 33089377 [TBL] [Abstract][Full Text] [Related]
8. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732 [TBL] [Abstract][Full Text] [Related]
9. A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE. Schapkaitz E; Libhaber E; Gerber A; Rhemtula H; Zamparini J; Jacobson BF; Büller HR Clin Appl Thromb Hemost; 2023; 29():10760296231160748. PubMed ID: 36972476 [TBL] [Abstract][Full Text] [Related]
10. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related]
11. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123 [TBL] [Abstract][Full Text] [Related]
12. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222 [TBL] [Abstract][Full Text] [Related]
13. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028 [TBL] [Abstract][Full Text] [Related]
14. Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. Benes J; Skulec R; Jobanek J; Cerny V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):204-210. PubMed ID: 34042098 [TBL] [Abstract][Full Text] [Related]
15. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Atallah B; Sadik ZG; Salem N; El Nekidy WS; Almahmeed W; Park WM; Cherfan A; Hamed F; Mallat J Anaesthesia; 2021 Mar; 76(3):327-335. PubMed ID: 33047335 [TBL] [Abstract][Full Text] [Related]
16. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617 [TBL] [Abstract][Full Text] [Related]
17. Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism. Vincent LE; Talanker MM; Butler DD; Zhang X; Podbielski JM; Wang YW; Chen-Goodspeed A; Hernandez Gonzalez SL; Fox EE; Cotton BA; Wade CE; Cardenas JC JAMA Surg; 2022 Aug; 157(8):713-721. PubMed ID: 35731524 [TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V; N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003 [TBL] [Abstract][Full Text] [Related]
19. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. Lin H; Faraklas I; Saffle J; Cochran A J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887 [TBL] [Abstract][Full Text] [Related]